NCT03353909

The Efficacy of A New Crosslinked Hyaluronan Gel in Prevention of Intrauterine Adhesion

Completed NA Last updated 27 November 2017

What this trial tests

NA trial testing new crosslinked hyaluronan gel in Intrauterine Adhesion in 300 participants. Completed in 15 February 2017.

Timeline

1 July 2016

Primary endpoint
15 February 2017

15 February 2017

Quick facts

Lead sponsor	BioRegen Biomedical (CHangzhou) Co., Ltd
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	300
Start date	1 July 2016
Primary completion	15 February 2017
Estimated completion	15 February 2017

Drugs / interventions tested

• new crosslinked hyaluronan gel

Conditions studied

• Intrauterine Adhesion — all drugs for Intrauterine Adhesion →

Sponsor

BioRegen Biomedical (CHangzhou) Co., Ltd

Who can join

Adults 18 to 45, female only, with Intrauterine Adhesion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Using American Fertility Society classification of intrauterine adhesions, the efficacy of a new crosslinked hyaluronan gel in reducing intrauterine adhesion formation after dilatation and curettage for delayed miscarriage in women without previous dilatation and curettage was examined.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Biomaterializing the advances in uterine tissue engineering.
   Wei Z, Hu Y, He X, Ling W, et al · · 2022 · cited 13× · PMID 36536678 · DOI 10.1016/j.isci.2022.105657